Novem Group Acquires New Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Novem Group bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 1,038 shares of the biopharmaceutical company's stock, valued at approximately $739,000.

Several other hedge funds have also modified their holdings of the company. OLD Second National Bank of Aurora raised its position in shares of Regeneron Pharmaceuticals by 0.5% in the 4th quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company's stock valued at $2,025,000 after purchasing an additional 15 shares during the last quarter. Rakuten Securities Inc. grew its position in Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 15 shares during the period. TD Private Client Wealth LLC grew its position in Regeneron Pharmaceuticals by 9.6% during the fourth quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock valued at $122,000 after buying an additional 15 shares during the period. Manchester Capital Management LLC grew its position in Regeneron Pharmaceuticals by 12.6% during the fourth quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company's stock valued at $115,000 after buying an additional 18 shares during the period. Finally, Financial Perspectives Inc grew its position in shares of Regeneron Pharmaceuticals by 10.9% in the fourth quarter. Financial Perspectives Inc now owns 193 shares of the biopharmaceutical company's stock valued at $137,000 after purchasing an additional 19 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on REGN. Royal Bank of Canada dropped their target price on shares of Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 30th. Bernstein Bank reduced their target price on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Bank of America reduced their target price on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a research note on Thursday, April 17th. JPMorgan Chase & Co. reduced their price target on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating on the stock in a research note on Monday, March 31st. Finally, Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $890.60.

Regeneron Pharmaceuticals Stock Down 1.4%

Shares of NASDAQ REGN traded down $8.51 during mid-day trading on Friday, reaching $588.34. The company had a trading volume of 655,734 shares, compared to its average volume of 801,377. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm has a 50 day simple moving average of $592.38 and a two-hundred day simple moving average of $674.96. The stock has a market cap of $63.52 billion, a P/E ratio of 15.37, a PEG ratio of 2.34 and a beta of 0.43. Regeneron Pharmaceuticals, Inc. has a 52-week low of $520.50 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. During the same period in the previous year, the business posted $9.55 earnings per share. The company's revenue for the quarter was down 3.7% on a year-over-year basis. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.60%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.